Skip to main content

Tivozanib Outperforms Sorafenib as First-Line Treatment in Advanced Renal-Cell Carcinoma

August 2012 Vol 5, No 5, Special Issue ASCO 2012 Payers' Perspective - Renal-Cell Carcinoma

Chicago, IL—Tivozanib, a potent in­vestigational tyrosine kinase inhibitor with a long half-life, demonstrated significant improvement in progression-free survival (PFS) as first-line targeted therapy for metastatic renal-cell carcinoma (mRCC), according to results from a phase 3 randomized, open-label trial.

The results suggest that “tivozanib should be considered a first-line treatment option for metastatic RCC,” said Robert Motzer, MD, an oncologist at Memorial Sloan-Kettering Cancer Center, New York, and the trial’s lead investigator.

Tivozanib targets all 3 vascular endothelial growth factor (VEGF) receptors and is designed to optimize blockade while minimizing off-target toxicities. The long half-life permits once-daily dosing.

Impressive phase 2 safety data for tivozanib warranted a phase 3 trial comparing tivozanib with sorafenib in patients with mRCC as first-line, targeted therapy.

The study included 517 patients with mRCC, who were randomized to tivozanib once daily for 3 weeks (followed by 1 week of rest) or sorafenib twice daily continuously in a 4-week cycle. Patients were either treatment-naive or had received no more than 1 prior systemic therapy for metastatic disease. Treatment continued until  disease progression or intolerance.

Patients randomized to the soraf­enib arm were eligible to cross over to tivozanib therapy under a separate protocol after radiographic confirmation of disease progression, and many of them did. No crossover protocol was available for patients randomized to the tivozanib arm.

In the overall study population, tivozanib demonstrated significant improvement in PFS compared with sorafenib (median, 11.9 months vs 9.1 months) when assessed by an independent panel, correspond­ing to a 21% improvement with tivozanib. When assessed by the investigators, the difference in PFS between the 2 groups was 14.7 months with tivozanib versus 9.6 months for sorafenib. The efficacy advantage of tivozanib was consistent across all subgroups.

Among the 70% of treatment-naive patients, median PFS was 12.7 months with tivozanib versus 9.1 months with sorafenib, and the objective response rate was 33% versus 23%, respectively.

The tolerability of tivozanib was also more favorable than sorafenib’s, as evidenced by a low rate of dose interruptions (17% vs 35%, respectively) and reductions (12% vs 43%, respectively).

Treatment-emergent adverse events occurred in 90% of patients in both groups, although important differences were seen in the safety profile between the 2 drugs.

According to Dr Motzer, although hypertension is the predominant adverse event with tivozanib, the development of hypertension is associated with tivozanib’s greater efficacy and potency for the VEGF receptor. The hypertension was treatable, re­quiring dose reduction in only 2% and dose discontinuation in only 1% of the patients treated with tivozanib.

“There’s clear evidence that the phase 2 safety profile has indeed been confirmed in phase 3,” said coinves­tigator Tim Eisen, MD, Professor
of Medical Oncology, Cambridge Research Institute, United Kingdom. The data require more careful evaluation over the next several months to “exclude any hypertension-related complication risk,” he said.

Related Items
Adjuvant Pembrolizumab Therapy Significantly Extends Disease-Free Survival in Patients with Clear-Cell Renal-Cell Carcinoma
Phoebe Starr
August 2021 Vol 14, Special Issue: Payers' Perspectives in Oncology published on August 9, 2021 in Renal-Cell Carcinoma, Conference Highlights ASCO
Avelumab plus Axitinib New First-Line Standard of Care in Advanced Renal-Cell Carcinoma
Chase Doyle
August 2019, Vol 12, Special Issue: Payers' Perspectives In Oncology: ASCO 2019 Highlights published on August 16, 2019 in Renal-Cell Carcinoma
First-Line Treatments for Metastatic Renal-Cell Carcinoma Are Evolving
August 2012 Vol 5, No 5, Special Issue ASCO 2012 Payers' Perspective published on August 29, 2012 in Renal-Cell Carcinoma
Axitinib Dose Titration Up Enhances Outcomes in Metastatic Renal-Cell Carcinoma
Wayne Kuznar
August 2012 Vol 5, No 5, Special Issue ASCO 2012 Payers' Perspective published on August 29, 2012 in Renal-Cell Carcinoma
Quality of Life Drives Patient Preference for Metastatic RCC Drug
Wayne Kuznar
August 2012 Vol 5, No 5, Special Issue ASCO 2012 Payers' Perspective published on August 29, 2012 in Renal-Cell Carcinoma
Last modified: August 30, 2021